Skip to main content

Advertisement

Table 1 Baseline patient demographics and clinical characteristics

From: High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting

  Patients treated with SOF/VEL, 12 weeks (n = 9) Patients treated with SOF/DCV (n = 32) P value
24 weeks (n = 12) 12 weeks (n = 20)
Mean age (years) 37.44 ± 9.51 49.17 ± 9.10 39.35 ± 9.64 0.021
Sex     0.458
 Male, n (%) 7 (77.8) 11 (91.7) 15 (75)  
 Female, n (%) 2 (22.2) 1 (8.3) 5 (25)  
History of drug abuse     0.907
 Yes, n (%) 6 (66.7) 7 (58.3) 13(65)  
 No, n (%) 3 (33.3) 5 (41.7) 7 (35)  
Cirrhosis status     0.041
 Without cirrhosis, n (%) 7 (78) 6(50) 18(90)  
 With compensated cirrhosis, n(%) 2 (22) 6 (50) 2 (10)  
Renal impairment     0.258
 Yes, n (%) 0 2 (16.7) 1 (5)  
 No, n (%) 9 (100) 10 (83.3) 19 (95)  
Previously treated, n (%)     0.414
 Yes, n (%) 1 (11.1) 0 (0) 1 (5)  
 No, n (%) 8 (88.9) 12 (100) 19 (95)  
Baseline HCV RNA (IU/mL)* 6.02 ± 1.08 5.64 ± 1.74 6.18 ± 1.12 0.840
Platelet (× 109/L) 157 ± 61.23 102.2 ± 32.11 164 ± 76.57 0.321
Albumin (g/L) 43.05 ± 2.92 39.36 ± 7.22 39.62 ± 6.68 0.871
ALT (IU/L) 193.06 ± 174.35 46.82 ± 22.07 83.60 ± 82.91 0.082
AST (IU/L) 70.89 ± 47.99 102.20 ± 32.11 69.74 ± 71.22 0.647
Total bilirrubin (μmol/L) 11.08 ± 6.99 11.38 ± 1.99 38.21 ± 66.51 0.585
  1. Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, DCV daclatasvir, HCV hepatitis C virus, SOF sofosbuvir, VEL velpatasvir. * log transformations